0001609351-16-000099.txt : 20160919 0001609351-16-000099.hdr.sgml : 20160919 20160919163703 ACCESSION NUMBER: 0001609351-16-000099 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160915 FILED AS OF DATE: 20160919 DATE AS OF CHANGE: 20160919 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Spark Therapeutics, Inc. CENTRAL INDEX KEY: 0001609351 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 462654405 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3737 MARKET STREET STREET 2: SUITE 1300 CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: 888-772-7560 MAIL ADDRESS: STREET 1: 3737 MARKET STREET STREET 2: SUITE 1300 CITY: PHILADELPHIA STATE: PA ZIP: 19104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: High Katherine A CENTRAL INDEX KEY: 0001631248 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36819 FILM NUMBER: 161892109 MAIL ADDRESS: STREET 1: 3737 MARKET STREET STREET 2: SUITE 1300 CITY: PHILADELPHIA STATE: PA ZIP: 19104 4 1 wf-form4_147431741062378.xml FORM 4 X0306 4 2016-09-15 0 0001609351 Spark Therapeutics, Inc. ONCE 0001631248 High Katherine A C/O SPARK THERAPEUTICS, INC. 3737 MARKET STREET, SUITE 1300 PHILADELPHIA PA 19104 1 1 0 0 See Remarks Common Stock 2016-09-15 4 S 0 9500 60.33 D 220500 D Common Stock 2016-09-15 4 S 0 500 61.20 D 220000 D The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2016. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.82, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.15 to $61.25, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. President and Chief Scientific Officer /s/ Joseph W. La Barge, attorney-in-fact for Katherine A. High 2016-09-19